Ozempic and Mounjaro Are Linked to Hair Loss: What the July 2026 Study Means and How to Protect Yourself

Millions of Americans taking GLP-1 medications like Ozempic and Mounjaro have reported an unsettling side effect that isn’t prominently listed on the package insert: noticeable hair loss. A large study published July 23, 2026 has now formally confirmed what many patients have been experiencing: GLP-1 drugs may significantly increase the risk of hair loss in people with type 2 diabetes — with users having higher rates of alopecia compared to those taking other common diabetes medications.

As a pharmacist with 40 years of clinical experience, hair loss is one of the most distressing side effects patients report across many medication classes — and its emergence as a documented GLP-1 concern deserves a complete, honest explanation. Understanding why it happens, how common it is, and what can be done about it is essential for anyone on these medications.

The July 2026 Study: The Numbers

The large observational study compared hair loss (alopecia) rates in GLP-1 users versus users of two other common diabetes medication classes — DPP-4 inhibitors (sitagliptin/Januvia) and SGLT2 inhibitors (empagliflozin/Jardiance). The GLP-1 users showed significantly higher rates of alopecia diagnoses over the follow-up period.

The absolute risk increase remained relatively modest — but statistically meaningful, and clinically important given the tens of millions of Americans now taking GLP-1 medications. The researchers called for better patient counseling about this risk, which has been underemphasized in prescribing discussions.

Why GLP-1 Drugs May Cause Hair Loss

1. Telogen Effluvium From Rapid Weight Loss

The most likely primary mechanism is telogen effluvium — a form of hair loss triggered by significant physiological stress, including rapid weight loss. When the body loses weight quickly, hair follicles prematurely enter the telogen (resting/shedding) phase of the hair growth cycle. The dramatic caloric restriction and weight loss produced by GLP-1 medications — which can reach 15-28% of body weight — creates significant metabolic stress on hair follicles.

Telogen effluvium typically begins 2-4 months after the triggering event (the period of rapid weight loss) and involves diffuse hair shedding across the scalp rather than patchy loss. The good news: telogen effluvium is generally temporary — hair typically regrows once weight loss stabilizes.

2. Nutritional Deficiencies From Reduced Food Intake

GLP-1 drugs dramatically suppress appetite — often reducing food intake by 30-50%. This appetite suppression, while beneficial for weight loss, creates significant risk of micronutrient deficiency when patients don’t actively ensure nutritional adequacy within reduced caloric intake. Key nutrients whose deficiency causes hair loss:

Iron/ferritin: Iron deficiency is the most common nutritional cause of hair loss in women; ferritin below 50 ng/mL significantly impairs hair follicle function
Protein: Inadequate protein during active weight loss triggers hair loss; hair follicles require amino acids for keratin synthesis
Zinc: Critical for hair follicle cell proliferation; deficiency causes diffuse hair shedding
Biotin: Cofactor for keratin synthesis; can be depleted with significant dietary restriction
Vitamin D: Deficiency associated with hair follicle cycling disruption

3. Direct GLP-1 Receptor Effects on Hair Follicles

GLP-1 receptors are present in hair follicle tissue. Some researchers propose that direct GLP-1 receptor activation may alter hair follicle cycling — potentially extending the telogen phase or shortening the anagen (growth) phase. This mechanism would explain hair loss independent of weight loss magnitude and nutritional status, and is an area of active investigation.

How Common Is It and Who Is Most at Risk?

The July 2026 study found meaningfully higher rates in GLP-1 users versus other diabetes drug classes
Women appear at higher overall risk (given baseline higher rate of female pattern hair loss and iron deficiency)
Those experiencing the fastest and most dramatic weight loss are at greatest risk
Patients with pre-existing iron deficiency or low ferritin before starting GLP-1 treatment are particularly vulnerable
Hair loss typically begins 2-6 months after starting treatment or after a period of rapid weight loss

The Pharmacist’s Prevention and Management Protocol

Before Starting GLP-1 Medication

Get baseline ferritin, iron, zinc, vitamin D, and complete blood count — identify deficiencies before starting
Correct any identified nutritional deficiencies proactively
Discuss hair loss risk with your prescribing physician so it’s not alarming if it occurs

Priority #1: Adequate Protein — Non-Negotiable

Target 1.2-1.5g protein per pound of goal body weight daily — even on suppressed appetite. Protein is the most critical nutritional factor for hair preservation during GLP-1 treatment. Prioritize protein at every eating occasion. Protein shakes, Greek yogurt, eggs, and cottage cheese are efficient high-protein, low-volume foods for appetite-suppressed patients.

Priority #2: Iron and Ferritin Monitoring

Check ferritin every 3-6 months while on GLP-1 medications, especially women. Target ferritin above 50 ng/mL for hair health (higher than the “normal” laboratory range). If ferritin is low-normal or below 50, iron supplementation (iron glycinate or ferrous bisglycinate — better tolerated than ferrous sulfate) may help.

Key Supplements for GLP-1 Hair Protection

Zinc (8-11mg daily, not to exceed 40mg): Hair follicle enzyme cofactor; take with food
Vitamin D3 (correct to 50-60 ng/mL): Hair follicle cycling support
Collagen peptides (10-15g with vitamin C): Provides amino acid substrates for keratin; emerging evidence for hair support
Biotin (2,500-5,000mcg daily): Note: stop 3-5 days before any lab work — biotin interferes with thyroid, troponin, and hormonal blood tests

Slow the Rate of Weight Loss

If hair loss is significant, discuss with your physician about slowing dose escalation or extending time between dose increases. A more gradual weight loss rate (0.5-1% of body weight per week maximum) dramatically reduces telogen effluvium risk.

Topical Options

For persistent hair thinning, minoxidil (Rogaine) — available OTC for women (2%) and men (2%, 5%) — has the strongest clinical evidence for hair regrowth. Discuss with your dermatologist if hair loss is significant or prolonged beyond 6 months.

The Bottom Line

The July 2026 GLP-1 hair loss study is an important reminder that all effective medications have real side effect profiles. Hair loss is distressing but manageable — and for most patients, it is temporary and nutritionally preventable with proactive management. After 40 years of pharmacy practice, my guidance is clear: start GLP-1 medication with a nutritional assessment, hit your protein targets aggressively, monitor ferritin, and don’t be surprised by temporary hair shedding. The weight loss and metabolic benefits of GLP-1 therapy significantly outweigh this side effect for most appropriate patients — but going in informed makes the experience far less alarming.

Disclaimer: Our content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you are experiencing significant hair loss on GLP-1 medications, consult your physician and consider a dermatology referral. Always seek the advice of your healthcare provider.